Lupus treatment hope from Japanese miRNA research
A group of researchers from the Graduate School of Medicine at Nagoya University in Japan…
January 26, 2023 - 5 minutes
mRNA: A New Technology Moving into the Mainstream
Messenger RNA (mRNA) technology is based on the idea that human cells can be used as on-demand factories to develop therapeutic proteins by giving them instructions in the form of mRNA. Although mRNA therapeutics and vaccines could be found in drug development pipelines before Covid-19 emerged, the pandemic suddenly moved the mRNA technology into the limelight.
Now, the world has seen mass vaccinations using mRNA-based vaccines developed by Moderna and Pfizer/BioNTech. But the mRNA technology holds promise for other indications as well, including cancer and rare diseases. Read on to learn how this new technology is moving into the mainstream with an influx of investments and new discoveries.
Show More
Editor's Picks for mRNA technology
- Could mRNA Vaccines Fulfill Their Potential Against Coronavirus?
- The COVID-19 pandemic has driven RNA therapeutics into the mainstream
- EMA Greenlights BioNTech and Pfizer mRNA Vaccine for Covid-19
- Next-Generation mRNA Vaccine Technology Unveiled in Series A Round
- Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology
European Biotech Industry Report 2021
This report discusses how the Covid-19 pandemic impacted Europe’s life science industry and covers recent market trends, investments, and collaborations.
Go to ReportLatest mRNA technology Articles
Watch: pHion Therapeutics talks about next-generation mRNA vaccines
pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic…
January 23, 2023 - 1 minute
AbbVie bets on Anima mRNA modulators to tackle cancer
AbbVie and Anima Biotech have announced a collaboration to discover and develop mRNA biology modulators…
January 11, 2023 - 2 minutes
BioNTech partnering with UK Government on personalized mRNA cancer immunotherapies
BioNTech SE has signed a memorandum of understanding (MoU) with the Government of the United…
January 6, 2023 - 4 minutes
2023 Editorial Calendar updated
Each month here at Labiotech.eu, we produce a special newsletter. While still news-related, these special…
January 5, 2023 - 3 minutes
Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine
Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine…
December 21, 2022 - 3 minutes
Providence Therapeutics’ mRNA rabies vaccine hits milestone
Providence Therapeutics Holdings Inc. says its new mRNA vaccine program for rabies post-exposure prophylaxis has…
December 16, 2022 - 2 minutes
ExPLoRNA Therapeutics receives mRNA technology funding
ExPLoRNA Therapeutics, a Polish biotech company working on mRNA vaccines and therapeutics, has received funding…
December 7, 2022 - 2 minutes
AI works on artificial DNA for future drug development
With the help of artificial intelligence (AI), researchers at Chalmers University of Technology in Sweden…
November 24, 2022 - 4 minutes
BIA and Exopharm sign joint research agreement to develop integrated technology
Slovenian-based Sartorius BIA Separations (BIA), a bio-chromatography company, and Australia's Exopharm Ltd., a company working…
November 23, 2022 - 4 minutes
Agreement boosts mRNA manufacturing in Singapore
RVAC Medicines Pte. Ltd., a messenger RNA (mRNA) technology platform company, and the Agency for…
November 21, 2022 - 2 minutes
Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy
Nutcracker Therapeutics, Inc. has presented the first set of preclinical data for its lead oncology…
November 14, 2022 - 3 minutes
